Collins Stewart Maintains a 'Buy' on Human Genome Sciences (HGSI); April Benlysta Tracking Survey Suggests Encouraging Early Trends

Collins Stewart maintains a 'Buy' on Human Genome Sciences (NASDAQ: HGSI), PT $25.

Collins analyst says, "We are encouraged by the early uptake in April (2/30 physicians treated 9 patients) and expected uptake for May (12/30 physicians expect to treat 38 patients), particularly given: 1) the early stage of the launch (March 25; only 60% had been visited by a sales rep) and 2) initial reimbursement hurdles (5 physicians are waiting for formulary approval). We believe these early trends, including physician awareness (rated a 7.2/10) are positive, but await further clarity from our May and June surveys."

For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.

Shares of Human Genome Sciences closed at $25.00 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery